A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

NCT05754853 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

290

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Urothelium Cancer

Interventions

DRUG: MRG002
DRUG: Docetaxel Injection
DRUG: Paclitaxel Injection
DRUG: Gemcitabine Hydrochloride for Injection
DRUG: Pemetrexed Disodium Injection

Sponsor

Shanghai Miracogen Inc.